MeiraGTx/$MGTX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About MeiraGTx
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
Ticker
$MGTX
Sector
Primary listing
Employees
386
Headquarters
Website
MeiraGTx Metrics
BasicAdvanced
$689M
-
-$2.03
1.30
-
Price and volume
Market cap
$689M
Beta
1.3
52-week high
$9.50
52-week low
$4.55
Average daily volume
392K
Financial strength
Current ratio
0.881
Quick ratio
0.729
Long term debt to equity
2,629.122
Total debt to equity
2,718.547
Interest coverage (TTM)
-12.29%
Profitability
EBITDA (TTM)
-145.318
Gross margin (TTM)
26.56%
Net profit margin (TTM)
-415.39%
Operating margin (TTM)
-416.49%
Revenue per employee (TTM)
$100,000
Management effectiveness
Return on assets (TTM)
-42.42%
Return on equity (TTM)
-379.53%
Valuation
Price to revenue (TTM)
17.523
Price to book
232.65
Price to tangible book (TTM)
310.47
Price to free cash flow (TTM)
-4.96
Free cash flow yield (TTM)
-20.16%
Free cash flow per share (TTM)
-1.726
Growth
Revenue change (TTM)
366.84%
Earnings per share change (TTM)
36.36%
3-year revenue growth (CAGR)
-5.11%
3-year earnings per share growth (CAGR)
-3.69%
What the Analysts think about MeiraGTx
Analyst ratings (Buy, Hold, Sell) for MeiraGTx stock.
Bulls say / Bears say
MeiraGTx and Hologen received clearances under UK FDI laws and secured $23 million of the $200 million upfront payment in Q2 2025, advancing joint venture formation and bolstering near-term liquidity (MeiraGTx Q2 results).
The FDA granted RMAT designation to AAV-GAD on May 8, 2025, providing Fast Track and Breakthrough Therapy benefits and enabling rolling BLA review that de-risks the regulatory path for MeiraGTx’s Parkinson’s gene therapy (Nasdaq).
MeiraGTx filed for Marketing Authorization Approval under exceptional circumstances for AAV-AIPL1 with the UK’s MHRA and aligned with the FDA on CMC requirements for its Phase 2 AAV-hAQP1 xerostomia study, positioning both programs for potential expedited approval (MeiraGTx Q1 results).
As of June 30, 2025, MeiraGTx has only received $23 million of the $200 million upfront payment from Hologen AI, with the remaining $177 million subject to closing conditions, posing near-term liquidity risks if delays occur (SEC 10-Q).
Under the Hologen Neuro AI joint venture, MeiraGTx holds only a 30% ownership stake, ceding majority control and limiting its capture of upside from the fully funded AAV-GAD program (MeiraGTx Q2 results).
Weiss Ratings reaffirmed a 'Sell (D-)' rating on MeiraGTx on October 25, 2025, reflecting concerns over sustained negative net margins and recent insider share sales, indicating potential governance and financial stability issues (MarketBeat).
Data summarised monthly by Lightyear AI. Last updated on 2 Nov 2025.
MeiraGTx Financial Performance
Revenues and expenses
MeiraGTx Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for MeiraGTx stock?
MeiraGTx (MGTX) has a market cap of $689M as of November 05, 2025.
What is the P/E ratio for MeiraGTx stock?
The price to earnings (P/E) ratio for MeiraGTx (MGTX) stock is 0 as of November 05, 2025.
Does MeiraGTx stock pay dividends?
No, MeiraGTx (MGTX) stock does not pay dividends to its shareholders as of November 05, 2025.
When is the next MeiraGTx dividend payment date?
MeiraGTx (MGTX) stock does not pay dividends to its shareholders.
What is the beta indicator for MeiraGTx?
MeiraGTx (MGTX) has a beta rating of 1.3. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.